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Abstract
Purpose Androgenetic alopecia, commonly known as male
pattern baldness, is the most common type of progressive
hair loss disorder in men. The aim of this paper is to review
recent advances in understanding the pathophysiology and
molecular mechanism of androgenetic alopecia.
Methods Using the PubMed database, we conducted a
systematic review of the literature, selecting studies pub-
lished from 1916 to 2016.
Results The occurrence and development of androgenetic
alopecia depends on the interaction of endocrine factors and
genetic predisposition. Androgenetic alopecia is character-
ized by progressive hair follicular miniaturization, caused
by the actions of androgens on the epithelial cells of
genetically susceptible hair follicles in androgen-dependent
areas. Although the exact pathogenesis of androgenetic
alopecia remains to be clarified, research has shown that it is
a polygenetic condition. Numerous studies have unequi-
vocally identified two major genetic risk loci for androge-
netic alopecia, on the X-chromosome AR⁄EDA2R locus and
the chromosome 20p11 locus.
Conclusions Candidate gene and genome-wide association
studies have reported that single-nucleotide polymorphisms
at different genomic loci are associated with androgenetic
alopecia development. A number of genes determine the
predisposition for androgenetic alopecia in a polygenic
fashion. However, further studies are needed before the
specific genetic factors of this polygenic condition can be
fully explained.
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Introduction
Androgenetic alopecia (AGA), also known as androgenic
alopecia or male pattern baldness, is the most common type
of progressive hair loss. AGA is a polygenetic condition
with varying severity, age of onset, and scalp location of
hair loss. In men, hair loss typically involves the temporal
and vertex region while sparing the occipital region: the
characteristic “horseshoe” pattern.
Incidence and prevalence of AGA depend on age and
race. Based on the little prevalence data available, we know
that up 30% of white men will have AGA by the age of 30
years, up to 50% by 50 years, and 80% by 70 years [1–3].
Chinese, Japanese, and African American people are less
affected than Caucasians [4].
AGA features a progressive miniaturization of the hair
follicle leading to vellus transformation of terminal
hair. This results from an alteration in hair cycle dynamics:
anagen phase duration gradually decreases and that
of the telogen phase increases. As the anagen phase
duration determines hair length, the new anagen
hair becomes shorter, eventually leading to bald appearance
[5, 6].
In 1951, Hamilton referred to the mutual interplay of
androgens, genetic and age factors in the origin of AGA [1].
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Hamilton’s observations on hypogonadal men established
that androgens were prerequisites for the development of
common baldness: men castrated before puberty did not
develop AGA, and AGA could be triggered in castrated
men by injecting testosterone.
Although these changes are driven by androgens, most of
the molecular mechanisms are unknown, limiting available
treatments.
Predisposition to AGA predominantly depends on
genetics. Twin studies show strong concordance rates of
between 80 and 90% for monozygotic twins. Family ana-
lyses show a significantly increased risk for AGA in men
with a bald father [7], while the risk is significantly
decreased in men with a non-balding father. However, the
risk of developing AGA also increases with a positive
family history on the side of the mother, or of the maternal
grandfather [7]. This transmission through many successive
generations suggests the involvement of a single major
gene.
In 1916, Osborn proposed that the pattern of AGA may
be consistent with an autosomal dominant trait [8]. Kuster
and Happle reviewed the genetics of AGA and concluded
that Osborn’s hypothesis had not been thoroughly tested and
was thus of questionable validity [9]. In their analysis of
five previous studies, they concluded that a polygenic mode
of inheritance was more likely. The current scientific data
support the thesis that AGA has a polygenic trait, but its
pathophysiology and genetics are not fully understood.
Significant associations have been reported with variant
regions of the androgen receptor gene, located on the X-
chromosome. AGA is most likely a multifactorial disorder
caused by interactions among several genes and environ-
mental factors [10]. We aim to review recent advances in
the pathophysiology and molecular mechanism of AGA.
Androgens and hair follicles
Androgens affect several functions of the human skin,
including sebaceous gland growth and differentiation, hair
growth, the epidermal barrier, and wound healing, mainly
through a multi-step intracellular signaling pathway [11].
Although human hair growth is also affected by thyroid
hormones and glucocorticoid [12], androgens are the most
important regulators: they can stimulate, leave unaltered or
inhibit terminal hair growth, depending on the body site.
Androgens can enlarge the hair follicles in androgen-
dependent areas (beard, axillary, and pubic hair) but, para-
doxically, in scalp follicles of susceptible men, they sup-
press hair growth and promote miniaturization of and
shorter hair in the anagen stage, leading to common bald-
ness. Since the follicles are exposed to the same circulating
hormones, this paradox may be explained by gene expres-
sion response to androgens in different body areas [13].
Hair follicle biology over the last 20 years has estab-
lished the fundamental role of the mesenchyme-derived
dermal papilla in the maintenance of hair growth [14–16].
Dermal papilla cells (DPC) play an important role in the
induction and maintenance of epithelial cell growth [17] and
mediate the growth stimulating signals of androgens by
releasing growth factors that act in a paracrine fashion on
the other follicle cells [5]. More recently, the discovery of
higher levels of androgen receptors in cultured DPCs from
balding scalp hair follicles supported the hypothesis
developed by Randall et al. that androgens act on epithelial
cells of the hair follicle via the mesenchyme-derived dermal
papilla, stimulating some hair follicles (e.g. beard) while
inhibiting others, altering the production of regulatory fac-
tors [18].
This cross-talk between the dermal papilla and the hair
follicle cells results from the secretion of numerous growth
factors and/or extracellular matrix factors from the dermal
papilla [15, 19]. These growth factors have an autocrine
effect on the dermal papilla itself and a paracrine effect on
the hair follicle epithelial cells [20]. They include insulin
like growth factor 1 (IGF-1), basic fibroblast growth factor,
vascular endothelial growth factor, all of which stimulate
hair growth, and cytokines such as transforming growth
factor beta 1 (TGF-β1), interleukin 1 alpha, and tumor
necrosis factor alpha, with inhibitory and pro-apoptotic
effects [15, 21–23].
The regional specificity of androgen action is also partly
explained by in vitro experiments, where androgen stimu-
lation of scalp DPCs induced TGF-β1 production, while
stimulation of beard DPCs induced IGF-1 as a second
messenger [24]. Itami et al. observed that the synthetic
androgen R1881 suppressed keratinocyte growth in the
coculture of AR-overexpressing human DPCs from AGA
and normal human keratinocytes, through androgen-
inducible TGF-β1 [22, 25]. As TGF-β1 is known to be a
catagen inducer in hair cycling, it likely plays a role in the
early catagen induction seen in AGA [26]. Furthermore,
TGF-β2, dickkopf1, and IL-6 have been identified as
androgen-inducible negative mediators for AGA develop-
ment in several in vitro experimental methods, thus pro-
viding new clues for clarifying the details of androgen
action in AGA [27–29].
Androgen metabolism
Androgen action in hair follicles depends on their local
bioavailability. Even if most men with AGA have normal
circulating androgen levels, higher rates of testosterone and
dihydrotestosterone (DHT) are produced locally [30]. The
skin contains all the enzymatic equipment necessary for
androgen metabolism and can be considered as a peripheral
organ that locally synthesizes significant amounts of
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androgens with intracrine or paracrine actions [31].
The autonomous formation of androgens allows the
human skin to adjust their levels according to local
needs, and leads to different responses in the hair follicles
[32].
Testosterone is the major circulating androgen [33]. It
reaches the skin through capillary blood and it is converted
to the more potent androgen DHT by 5α-reductase (5αR) in
the cytoplasm. The weak androgens dehydroepiandroster-
one (DHEA), dehydroepiandrosterone-sulfate (DHEA-S),
and androstenedione are converted peripherally to the more
potent androgens testosterone and DHT. In the skin, the
conversion of DHEA, DHEA-S, and androstenedione into
more potent androgens occurs in sebocytes, sweat glands,
and DPCs [34]. In vitro studies have shown that specific
enzyme expression and activity in cultured sebocytes and
keratinocytes seem to allocate different duties to these cells
[32]. Sebocytes maintain androgen homeostasis by testos-
terone synthesis from adrenal precursors and its inactiva-
tion, whereas keratinocytes are responsible for androgen
degradation.
Androgen metabolism in the pilosebaceous units starts
from the desulfation of DHEA-S to DHEA by steroid sul-
fate synthase in dermal papilla. Next, 3β-hydroxysteroid
dehydrogenase—Δ5→4—isomerase (3β-HSD) type 1 con-
verts DHEA into androstenedione in the sebaceous glands
[32] and dermal papilla [35]. Subsequently, androstene-
dione is converted into testosterone by 17β-hydroxysteroid
dehydrogenase (17β-HSD). Human sebaceous glands pro-
vide the cellular machinery needed to transcribe the genes
for 17β-HSD types 1–5 [32, 36, 37]. 17β-HSD types 1, 3,
and 5 support the formation of more active androgens,
whereas the oxidative reaction induced by 17β-HSD types 2
and 4 deactivates them, indicating the possible role of
sebaceous glands in the regulation of local androgen
metabolism [32, 37]. Alternatively, DHEA can be converted
into androstenediol and testosterone by 17β-HSD and 3β-
HSD respectively in the pilosebaceous unit [38].
Two 5αR isoenzymes, type I (5αR1) and type II (5αR2),
irreversibly converts testosterone to DHT. 5αR1 is detected
in various androgen-independent organs such as the liver
and brain, while 5αR2 is predominantly observed in
androgen-dependent organs such as the epididymis and
prostate [39]. Inui et al. demonstrated that 5αR2 expression
is higher in DPCs from AGA and beard than in DPCs from
other sites [40, 41]. Once formed, testosterone and DHT can
be removed by conversion back to the weaker 17-
ketosteroids or can be metabolized via other enzymatic
pathways into estrogens via cytochrome P450 aromatase.
Aromatase activity is detectable in hair follicles [42], and its
expression in the outer root sheath of terminal hair follicles
in the anagen phase and in sebaceous glands [43] suggests a
local balance system for androgens and estrogens and that
hair follicles function as both targets and sources of estro-
gen [44].
Androgen concentration thus depends on the expression
of each of the androgen—and estrogen-synthesizing
enzymes in each cell type, with sebaceous and sweat
glands being the major contributors [13, 32]. For example,
changes in 5αR1 and 5αR2 expression and activity likely
increase conversion of testosterone to DHT within the hair
follicles [42]. Furthermore, androgen action is more com-
plex than that of other steroids. Testosterone itself binds to
receptors in some tissues, such as skeletal muscle, while in
others, including secondary sexual tissues like the prostate,
it is metabolized intracellularly by 5αR enzymes to DHT,
which binds more strongly to the AR to activate gene
expression [45, 46].
All androgen-dependent follicles require androgen
receptors (ARs) to respond, as proved by the absence of
adult body hair in individuals with complete androgen
insensitivity [47]. In contrast, the requirement for 5αR
varies with follicle site. Individuals with 5αR2 deficiency
only produce female patterns of pubic and axillary hair
growth, despite masculinization of their body shape [48],
suggesting that DHT is necessary for male specific follicles
(beard, chest, and upper pubic diamond), while testosterone
can stimulate the axilla and lower pubic triangle follicles
characteristic of women. It is unclear why some follicles
need DHT and others testosterone to stimulate the same cell
types, although it is likely that the cells use different
intracellular coactivator proteins. This appears to be another
paradox of androgen action in human follicles, presumably
due to differential gene expression within individual
follicles.
Androgen receptor (AR)
The effects of androgens are mediated through the AR, a
110-kDa ligand-inducible nuclear receptor that regulates the
expression of target genes through binding to an androgen
response element (ARE). Androgen binding changes the
AR’s protein conformation and leads to its dissociation from
the heat shock proteins and its translocation from the
cytoplasm to the nucleus, where it forms a homodimer and
is recruited to the ARE in the promoter regions of androgen-
regulated genes to initiate the signaling cascade. However,
it also undergoes intramolecular interactions that regulate its
interactions with coactivators and influence its activity. In
the skin, AR is found in epidermal and follicular keratino-
cytes, sebocytes, sweat gland cells, DPCs, dermal fibro-
blasts, endothelial cells, and genital melanocytes [32, 49,
50]. As in hair follicles it is localized not in epithelial cells
but in the dermal papillae, the latter are a major target for
androgen action [51, 52].
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DPCs from balding scalp hair follicles contain sig-
nificantly more androgen receptors than those derived from
non-balding follicles [18]. A recent study demonstrated that
DNA methylation of the AR promoter is increased in hair
follicles from the occipital scalp compared with those from
vertex AGA scalp [53]. Increased AR methylation, poten-
tially resulting in reduced AR expression, may protect
occipital hairs from miniaturization and hair loss.
Tissue-specific, distinct AR-associated coregulators
might explain the regional difference in hair follicle growth
in response to androgen stimulation. Hic-5/ARA55, a TGF-
β1-inducible AR co-activator, is highly expressed in DPCs
from androgen-sensitive sites such as AGA and beard,
suggesting that Hic-5/ARA55 can enhance androgen sen-
sitivity in DPCs [54, 55]. Hic-5/ARA55 acts as a scaffold
protein, which recruits or stabilizes chromatin modifying
coactivator complexes to target promoters. Hic-5/ARA55
levels were found to correlate with previously reported AR
levels in DPCs from various sites [18, 20]. Together, these
findings suggest that the sensitivity of hair follicles to
androgen is regulated through pre-receptor 5αR [56, 57],
ARs and post-receptor androgen co-activators [55]. On the
other hand, Lee et al. demonstrated a reduced ARA70b/
ELE1b expression in dermal papilla and hair bulbs from
balding hairs. As ARA70b/ELE1b promotes cell growth, it
is likely that this decrease contributes to the retardation of
hair follicle growth and eventually leads to hair follicle
miniaturization [58].
Genetics and pathogenesis of AGA
It has been established that AGA inheritance follows a
polygenic model, given its high prevalence and the wide
range of phenotypes.
As the androgen dependence of AGA is well established,
early studies focused on functional variants in or around AR
and on the two triplet-repeat polymorphisms of the trans-
activating domain: the polyglutamine (CAG) repeat lying
proximal and the polyglycine (GGN) repeat lying distal to
rs6152. In 1998, Sawaya et al. found that men with AGA
had shorter CAG repeats than did controls, and suggested
that CAG repeat length in AR may affect androgen-
mediated gene expression in hair follicles and sebaceous
glands [59]. In another study, the shorter polyglycine repeat
(GGN-23) was highly associated, suggesting that GGN-23
was closer to the AGA mutation or was itself the AGA-
susceptibility allele [60]. However, neither the CAG nor
GGN repeat polymorphisms appeared to be independently
responsible for the association with AGA [61].
Different AR polymorphism and AR restriction sites
were also investigated [62–67]. The StuI polymorphism was
linearly related to AR activity and associated with AGA
risk. The ubiquity of the AR gene StuI restriction site and
the higher incidence of shorter triplet repeat haplotypes in
bald men suggest that these markers are very close to a
functional variant that is a necessary component of the
polygenic determination of AGA. The AR-E211 A allele
was associated with a lower risk of alopecia, while the
EDA2R gene variation causes susceptibility to AGA [64].
Given the major role of the potent androgens testosterone
and DHT in hair follicle miniaturization, the 5αR enzyme
was investigated in the AGA pathogenesis. However, no
evidence was found that the gene for either of the two
isoforms of the steroid 5αR enzyme (SRD5A1 and
SRD5A2) is involved in the genetics of AGA [68].
The AGA susceptibility genes were also investigated in
autosomal regions, showing evidence for pathways other
than the classical androgen pathway. A susceptibility locus
was identified on chromosome 20p11 with a strong effect
on the development of early-onset AGA and no obvious
genetic connection to the androgen pathway [69]. A
genome-wide association study suggested a new AGA
susceptibility locus on chromosome 7p21.1, which is
located intronically in the histone deacetylase 9 (HDAC9)
gene [70]. HDAC9 was proposed as the third AGA sus-
ceptibility gene, as the major susceptibility genes are
unequivocally confirmed in AR and EDA2R while the
second strongest AGA susceptibility locus is on chromo-
some 20p11.7 [10, 62, 63, 67, 69, 71, 72]. The two AGA
susceptibility loci on the X chromosome and chromosome
20 were confirmed in a large-scale meta-analysis [73]. Six
new susceptibility loci also reached a genome-wide sig-
nificance and a risk allele at 17q21.31 was unexpectedly
identified on the gene intramembrane protease 5, recently
associated with Parkinson’s disease.
As DPCs from balding scalp contain higher levels of AR
than those from a non-balding scalp [18], the DPC pro-
liferation and differentiation were studied for their possible
role in the pathogenesis of AGA. The Wnt/β-catenin path-
way has been proposed as the main pathway involved
[74–76], since AR interacts with β-catenin in an androgen
dependent manner and their binding can inhibit Wnt sig-
naling [72, 77]. Furthermore, some studies have shown a
major role for Wnt signaling in regulating hair growth,
suggesting a functional cross talk between AR and Wnt
signaling pathways in target tissues [78–81]. Androgen
treatment induced a significant decrease in the cytoplasmic/
total β-catenin protein ratio and inhibition of canonical Wnt
in DPC [75]. These results suggest that androgens dereg-
ulate DPC-secreted factors involved in normal hair follicle
stem cell differentiation via the inhibition of the canonical
Wnt signaling pathway. Other candidate molecules for the
pathogenesis of AGA are the p63 protein, an important
regulator of hair follicle development, and CD34, a stem
cell marker [82, 83]. The prevalence of CD34+ in hair
follicles of the occipital scalp suggests that it might be key
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to hair follicle restoration and that its absence could con-
tribute to AGA progression. Another inhibitor of hair
growth in AGA was identified in the prostaglandin D2 [84].
However, a genome-wide association study failed to pro-
vide any genetic support for the role of prostaglandins in the
early causative chain of events that lead to AGA [85].
Oxidative stress is the latest candidate for a role in AGA
pathogenesis, as DPCs from male AGA patients underwent
premature senescence in vitro compared with occipital
DPCs in response to environmental stress [86–88]. Envir-
onmental oxygen significantly alters DPC morphology,
migration, proliferation, senescence, and TGF-β signaling
[89]. Bald DPCs were significantly more sensitive to oxi-
dative stress than were occipital DPCs and secreted higher
levels of negative hair growth regulators, TGF-β1, and β2,
in response to it.
Treatment
The choice of treatment for AGA depends on various fac-
tors including efficacy, practicability, risks, and costs. The
aim is to prevent the miniaturization process and, if possi-
ble, to reverse it. Treatments include pharmacotherapy,
surgery, and cosmetic aids. Despite the demand, there are
only two FDA-approved medications to treat AGA: the
potassium channel opener minoxidil, and the DHT synth-
esis inhibitor finasteride, both effective at controlling AGA
with long-term daily use. However, they are costly, require
lifelong treatment and may have side effects.
Medical therapy is most effective when started in the
early phases of hair loss and patients may elect to be treated
non-surgically only. Undoubtedly, medical therapy will
play a central role as an adjunct to surgical treatment by
preventing the loss of surrounding native hair and thus
enhancing the overall esthetic result.
Minoxidil
Minoxidil was originally developed as an antihypertensive
agent but attracted interest as a potential hair loss therapy,
when patients receiving this drug developed generalized
hypertrichosis [90]. This observation led to its topical for-
mulation, which has become a first-line treatment of pattern
hair loss. After application, minoxidil is converted to min-
oxidil sulfate, a potassium channel opener, which relaxes
vascular smooth muscle and increases blood flow [91]. In
vitro studies of hair growth have shown that hair cultures
grown in the presence of minoxidil maintain morphology,
whereas controls undergo kinking and necrosis [92].
Treatment results in increased hair weight with a less dra-
matic increase in hair count, suggesting that its therapeutic
effect is primarily due to increasing the diameter of existing
hairs. Topically applied minoxidil is currently available as
an over-the-counter preparation in either a 2 or 5% solution
or as a 5% foam. The response to treatment should be
assessed ideally at the end of 6 months. Patients should be
informed of telogen shedding, which is usually seen in the
first 8 weeks of therapy [93]. A common side effect is
contact dermatitis, which can initially be managed by
switching to a 2% solution or to the foam preparation,
which lacks propylene glycol [4]. Minoxidil treatment
requires two daily application indefinitely to maintain
results [4, 90, 91].
5a-reductase inhibitors (5aRi)
The importance of DHT as an etiologic factor in male AGA
is shown by the absence of this condition in men with a
congenital 5αR2 deficiency. Of the two 5aR isoenzymes in
humans [94, 95], type I predominates in the liver and skin,
including the scalp [96, 97, whereas type II is present in hair
follicles [98], as well as the prostate and genitourinary tract
[97]. Two 5αR inhibitors are used in AGA: finasteride, a
5αR2 inhibitor, and dutasteride, which inhibits both 5αR1
and 5αR2. The FDA approved finasteride in 1997 at a
dosage of 1 mg/day for use in adult men with mild-
moderate AGA. Oral dutasteride 0.5 mg a day is another
option, but there is a lack of studies comparing its efficacy
to finasteride. Oral finasteride lowers serum, prostate and
scalp DHT by approximately 60–70% [99]. Recent studies
also proved the efficacy of topical finasteride for AGA
[100–104]. Studies in both humans and animals have shown
that the combination of minoxidil 2% and finasteride 1 mg
is superior to monotherapies [105, 106].
The clinical efficacy of finasteride has been documented
in well-controlled clinical trials that monitored men with
AGA for up to 10 years [107]. Baldness progresses with
discontinuation of finasteride as DHT levels return to pre-
treatment levels. The response to treatment should be
assessed at 6 months, although in some men it may not
become evident until 12 months. Finasteride is generally
well tolerated with long-term daily use except for uncom-
mon sexual adverse effects, including gynecomastia,
reduced libido, erectile dysfunction, and ejaculatory dis-
orders. A study by Overstreet et al. showed that finasteride
1 mg daily for 48 weeks did not affect spermatogenesis or
semen production in men aged 19–41 years [108]. The
sexual symptoms of finasteride often diminish or resolve
with continued treatment and generally reverse on treatment
discontinuation. However, prolonged adverse effects on
sexual function such as erectile dysfunction, diminished
libido, depression, and decreased quality of life, are repor-
ted by a subset of men [109]. As the described symptoms
seem to apply to 5ARis in general and manifest mainly after
5ARi withdrawal, this condition has been identified as a
new medical problem, 5ARi Withdrawal Syndrome [110].
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The genotype of those affected is currently unknown. Not
all individuals are affected in the same way or to the same
degree. Some patients present only weak side effects, while
others suffer serious side effects, which include life-
threatening depression, severe muscle wasting, metabolic
syndrome, osteoporosis and complete loss of all sexual
function. These persistent side effects seem to relate to
physiological and psychological functions which require
androgens to function correctly. It has been hypothesized
that the mechanism of these persistent hypogonadal symp-
toms and loss of androgenic action are due to a form of
5ARi-induced androgen resistance as a consequence of AR
overexpression due to the decreased androgen (DHT)
availability. Since it shares a significant structural similarity
with testosterone and DHT, finasteride may interfere with
AR function, as proven in prostate cancer cell lines.
Finasteride may act as an AR-ligand in addition to its role as
a 5αR inhibitor not only in the prostate, but also in hair
follicles [111]. However, this antagonism, that could
explain the persisted side effects of finasteride, has not been
well characterized.
5ARi therapy may significantly reduce neurosteroid
biosynthesis, inducing depressive symptoms [112]. Neu-
roactive steroids are produced in the central nervous system
by transforming substrates from adrenal or gonadal steroids
to active neurosteroids [113]. Neurosteroids and neuroac-
tive steroids play an important role in memory enhancement
and have sedative, hypnotic, anesthetic, anxiolytic, antis-
tress, sleep modulating, anticonvulsant, and antidepressant
properties. A reduced concentration of circulating neu-
roactive steroids during finasteride treatment is probably an
important risk factor for depression.
Conclusion
Although the involvement of androgens in AGA is well
established and a pathophysiology pathway has been pro-
posed, further studies are needed to fully explain the genetic
basis of AGA. Few studies have attempted to identify
candidate genes for AGA because of its polygenic predis-
position. Transgenerational manifestations may involve the
Y chromosome or genes that are capable of parental
imprinting. Once the underlying biological mechanisms
have been established and our knowledge of the genetics
AGA has increased, new targeted treatments may emerge.
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